Why the FTC Is Challenging a Major Healthcare Merger
The US Federal Trade Commission is seeking to stop UnitedHealth Group from acquiring Amedisys, a major provider of home health and hospice services. The proposed deal, valued at about US$3.3 billion, would bring Amedisys under the ownership of Optum, UnitedHealth’s healthcare services division.
The regulator argues that the transaction could reduce competition in home-based medical care, particularly where UnitedHealth already owns LHC Group. The case raises questions about pricing, worker pay, patient choice and the growing role of large corporations in services traditionally delivered by local healthcare providers.
For Australians, the dispute is relevant because home nursing, aged care and hospital-at-home services are expanding in Sydney, Melbourne, Brisbane and regional communities. Decisions made in the US can also influence how policymakers assess consolidation in healthcare markets closer to home.
What The Proposed Deal Would Combine
Amedisys operates home health, hospice and personal care services across the United States. Its nurses and support staff visit patients in their homes, helping people recover after hospital treatment or receive end-of-life care without remaining in a facility.
UnitedHealth already has a substantial presence in home healthcare through LHC Group, which Optum acquired in 2023. The FTC says combining two significant providers could give UnitedHealth greater control over local markets, especially where patients, hospitals and insurers have relatively few alternatives.
Why Home Healthcare Matters
Home-based care has become more important as populations age and hospitals try to discharge patients sooner. It can be less expensive than inpatient treatment, while allowing people to remain near family and maintain familiar routines.
That growth has also increased competition for nurses, carers and therapists. If a single company controls several providers in the same area, the FTC believes it may have less incentive to offer higher wages or better conditions. The regulator is examining the effect on workers as well as patients and health plans.
The FTC’s Competition Argument
The agency’s lawsuit is based on antitrust principles. Its central claim is that UnitedHealth and Amedisys are direct competitors in certain local markets, so the merger could remove an important alternative for health plans that negotiate contracts for home healthcare.
The FTC may also examine how ownership could affect referrals. Hospitals and doctors frequently direct patients to home-care providers, while insurers decide which services receive coverage. A large integrated company could potentially influence several stages of that process, although UnitedHealth is expected to dispute the regulator’s interpretation.
What This Means For Australia
Australia has its own competition framework under the Competition and Consumer Act 2010, administered by the Australian Competition and Consumer Commission. The ACCC can challenge mergers when it believes they may substantially lessen competition, although Australia’s merger notification system has historically operated differently from the more formal US process.
The local market has distinct pressures. Medicare, private health insurance and aged-care funding often overlap, while home-care workers travel across spread-out suburbs and regional towns. A provider merger affecting services in Perth or Newcastle could have practical consequences when alternatives are already limited and families rely on regular visits.
The Price And Access Debate
Supporters of large healthcare groups often say scale can improve administration, technology and purchasing power. A bigger organisation may invest in digital scheduling, clinical records and coordinated care, which can help patients move between hospitals, homes and specialists.
Critics worry that efficiency claims can conceal reduced choice or higher prices. Similar debates appear in other regulated markets, where attempts to control costs can produce unexpected market effects. In healthcare, the consequences may involve delayed visits, fewer providers or lower service quality rather than changes to rent.
What Happens Next
The FTC’s complaint does not mean the merger has been legally rejected. UnitedHealth and Amedisys can contest the case in court, propose remedies or abandon the transaction. Possible remedies could include selling selected operations, though regulators may decide that divestitures would not fully restore competition.
The outcome will be watched by hospitals, insurers, investors and care workers. It may shape future deals involving hospice operators, home nursing networks and other healthcare companies that are seeking scale as demand rises.
Healthcare merger disputes can be difficult to follow because their effects are local, technical and spread across several parts of the economy. Follow daily news coverage for broader developments, and share this analysis with readers tracking regulation, business and public health.